| abstract |
The present invention relates to a chimeric antigen receptor (CAR) which is a recombinant chimeric protein capable of redirecting immune cell specificity and reactivity towards a selected membrane antigen, and more particularly, wherein the source of extracellular ligand binding is derived The scFV of the GD3 monoclonal antibody confers specific immunity against GD3-positive cells. Engineered immune cells with such CARs are particularly suitable for the treatment of solid tumors, such as melanoma, carcinoma, or liquid tumors, such as T-cell lymphoblastic leukemia. |